ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS SECRETS

In Segment A, contributors will get diverse doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. Added individuals will likely be enrolled in the discovered monotherapy dosign routine. In Phase B, members will obtain oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, members will receive